Vimta Labs has recommended a 1:1 bonus share issue and reported impressive financial results for FY 2024-25. Total income reached ₹3,482.22 crore, up 19.1% YoY, with PAT at ₹667.55 crore, up 36.8% YoY. The company declared a final dividend of ₹2 per share. Other key developments include expansion into Biologics CDMO, increased borrowing limit to ₹300 crore, appointment of new Secretarial Auditors, and reappointment of an Independent Director.
28Apr 25
Vimta Labs Reports Strong Q4 FY25 Results, Announces Bonus Shares and Expansion into Biologics
Vimta Labs reported robust Q4 and FY25 results with total income reaching ₹3,482.22 crore, up 19.1% year-on-year. Q4 FY25 saw a 31.4% increase in total income to ₹960.81 crore. The company declared a final dividend of ₹2 per share and recommended a 1:1 bonus share issue. Strategic initiatives include a ₹50 crore investment in Biologics CDMO, increased borrowing powers to ₹300 crore, and reappointment of Dr. Yadagiri R Pendri as Independent Director. Operational highlights include successful regulatory audits and expansion of laboratory spaces.
23Apr 25
Vimta Labs to Consider Q4 Results, Dividend, and Bonus Share Issue on April 28
Vimta Labs Limited has scheduled a board meeting for April 28, 2025, to approve Q4 and FY2025 financial results, consider dividend payment, and discuss a potential bonus share issue. The company has implemented a trading window closure from April 1, 2025, until 48 hours after the financial results announcement, in compliance with SEBI regulations.